The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
Table showing 2018 Disclosure UK data
|
2018 |
2017 |
|
What was the total transfer of value disclosed for 2018? |
£508.1 million |
£499.3 million |
|
How much did the industry spend on R&D collaborations with HCPs and HCOs? |
£377.3 million |
£370.9 million |
|
What percentage increase was there in R&D spend vs. the previous year? |
1.71% |
9.7% |
|
How much was spent on HCPs and HCOs for non-R&D collaborations? |
£130.8 million |
£128.4 million |
|
How much of the non-R&D value was against a named person or organisation? |
£108.7 million |
£104.8 million |
|
What percentage of the non-R&D value is disclosed against a named person or organisation? |
83.1% |
82% |
|
How much was spent on the following: |
|
||
|
Registration fees |
£3.5 million |
£3.9 million |
|
Sponsorship agreements with HCOs/3rd parties |
£28.9 million |
£23.9 million |
|
Travel and accommodation |
£9.8 million |
£10.1 million |
|
Donations and grants to HCOs |
£26.2 million |
£31 million |
|
Fees |
£50.5 million |
£48.9 million |
|
Related expenses agreed in the fee for services or consultancy contract |
£6.8 million |
£6 million |
|
Joint Working |
£5.2 million |
£4.6 million |
How many companies disclosed 2018 data? |
121 |
116 |
|
What was the consent rate for non-R&D spend to HCPs? |
57.2% |
49.1% |
|
*As defined in the ABPI Code of Practice, pharmaceutical companies must disclose their spend in individual categories. The following are some examples of what each category includes. More information in How we work with HCPs and How we work with HCOs.
Non-R&D spend includes:
[1] With some exceptions relating to how data is collected and processed. https://ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protection-regulation-gdpr/lawful-basis-for-processing/